Hans-Christian Kolberg, MD
Trastuzumab (Herceptin) has proven to be a go-to target in the development of biosimilars. MYL-1401O (Ogivri; trastuzumab-dkst) was approved by the FDA in December 2017, and agents such as SB3 and ABP 980 have shown similar pathologic complete response (pCR) rates to the originator biologic.
during the 2018 ASCO Annual Meeting, Kolberg, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discussed ABP 980 and the future of biosimilars in oncology.
OncLive: Can you provide some background on this study?
: The LILAC study was the registrational study for ABP 980, a biosimilar for the monoclonal antibody trastuzumab, which is used in HER2-positive breast cancer. In HER2-positive breast cancer, it is used in the early and metastatic stages. Trastuzumab is also approved for [patients with] HER2-positive gastric cancer.
... to read the full story